HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast caner
Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...
Theralase names Roger DuMoulin-White as president and CEO
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Roger DuMoulin-White as president and CEO, succeeding Arkady Mandel, M.D., Ph.D., as interim CEO. Dr. Mandel will continue as CSO and a director. Mr. DuMoulin...
Hepion to highlight AI-POWR at medical conference
Hepion Pharmaceuticals (NASDAQ:HEPA) will outline the integration of its artificial intelligence and machine learning platform, AI-POWR, into all aspects of its clinical pharmacological programs at the 2023 Canadian...
Pyxis Oncology to acquire Apexigen
Pyxis Oncology (NASDAQ:PYXS) agreed to acquire Apexigen (NASDAQ:APGN) in an all-stock transaction for an implied value of 64 cents per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares...
Wave Life flunks Phase 1b/2a study in ALS and dementia
Wave Life Sciences’ (NASDAQ:WVE) drug candidate, WVE-004, did not show clinical benefit, compared with placebo, in the Phase 1b/2a FOCUS-C9 study as an investigational treatment for C9orf72-associated amyotrophic...
T2 Biosystems exploring strategic alternatives
T2 BioSystems (NASDAQ:TTOO) initiated a process to explore a range of strategic alternatives focused on maximizing value and a restructuring plan, which includes a reduction in workforce. T2 has engaged an advisory firm...
MindBio gets ethics okay for take-home LSD-microdosing trial in MDD
MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received ethics approval for a world’s first Phase 2a take-home LSD-microdosing clinical trial in patients with major depressive disorder (MDD) in New Zealand. The...
Analysts give high marks to Hepion’s ATTITUDE NASH trial results
Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...
AVROBIO to sell cystinosis gene therapy program for $87.5-million
AVROBIO (NASDAQ:AVRO) agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5-million. Cystinosis is a rare, multisystem genetic...
Hepion Phase 2 ALTITUDE-NASH trial achieves all endpoints, improvement in liver function and NASH biomarkers
Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial with lead drug candidate, rencofilstat. ALTITUDE-NASH met its primary endpoint by...
Centessa receives FDA fast track in hemophilia B
The FDA granted fast track designation to Centessa Pharmaceuticals’ (NASDAQ:CNTA) SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia B, with or...
Hepion to release Phase 2 ALTITUDE-NASH results pre-market on May 22
Hepion Pharmaceuticals (NASDAQ:HEPA) expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial with its rencofilstat drug candidate before the market opens on Monday, May 22, 2023. The company...
Just a few of the companies we’ve highlighted along the way
